Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

316
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
316
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gluebodies Offer a Route To Improve Crystal Reliability and Diversity through Transferable Nanobody Mutations That Introduce Constitutive Close Contacts.

ACS central science·2025
Same author

Crystallographic Fragment Screen of Coxsackievirus A16 2A Protease identifies new opportunities for the development of broad-spectrum anti-enterovirals.

bioRxiv : the preprint server for biology·2024
Same author

An interrupted time series study of electronic health record clinical decision support for providers caring for patients with atrial fibrillation at increased stroke risk.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2023
Same author

State-of-the-Art Data Management: Improving the Reproducibility, Consistency, and Traceability of Structural Biology and in Vitro Biochemical Experiments.

Methods in molecular biology (Clifton, N.J.)·2020
Same author

Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.

Multiple sclerosis and related disorders·2020
Same author

Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2017

Related Experiment Video

Updated: Mar 20, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.

Elizabeth MacLean1, Laura Cisar2, Kimberly Mehle3

  • 11 Outcomes and Evidence, Global Health and Value, New York, New York.

Journal of Managed Care & Specialty Pharmacy
|May 28, 2016
PubMed
Summary

This study linked specialty pharmacy and claims data to analyze real-world axitinib use in advanced renal cell carcinoma (RCC) patients. Findings offer insights into treatment patterns and patient characteristics for optimizing therapy.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Real-world evidence

Background:

  • Axitinib is FDA-approved for advanced renal cell carcinoma (RCC) post-first-line therapy.
  • Real-world data are crucial for understanding patient profiles and utilization patterns beyond clinical trials.
  • Linking specialty pharmacy data with medical claims enhances understanding of treatment experiences.

Purpose of the Study:

  • To characterize real-world treatment patterns of axitinib as subsequent therapy in US patients with RCC.
  • To link specialty pharmacy data with medical and pharmacy claims databases for comprehensive analysis.

Main Methods:

  • Retrospective, observational cohort study linking specialty pharmacy and longitudinal medical/pharmacy claims data.
  • Included 1,175 patients with advanced RCC receiving axitinib as second-line or later therapy (May 2012-April 2013).
  • Analyzed patient demographics, comorbidities, prior therapies, treatment duration, and dose modifications.

Main Results:

  • Axitinib was used as second-line (56%), third-line (28%), and fourth-line or later (16%) therapy.
  • Mean treatment duration was 168.6 days; longer duration observed in males, patients in the Northeast, and those with hypothyroidism.
  • Sunitinib was the most common first-line therapy (56%) for second-line axitinib patients; 70% maintained the standard starting dose.

Conclusions:

  • Linking specialty pharmacy data with claims databases is feasible and valuable for understanding real-world treatment patterns.
  • Provides insights into the routine clinical use of axitinib and sequencing of targeted agents for advanced RCC.
  • Highlights patient, provider, and reimbursement characteristics influencing axitinib utilization.